The essential role of PIM kinases in sarcoma growth and bone invasion by Narlik-Grassow, Maja et al.
 1 1 
The essential role of PIM kinases in sarcoma growth and bone 
invasion 
 
 
Maja Narlik-Grassow1, Carmen Blanco-Aparicio1, Yolanda Cecilia1, Sandra 
Peregrina1, Beatriz Garcia-Serelde1, Sandra Muñoz-Galvan2, Marta Cañamero3 
and Amancio Carnero2,4* 
 
1) Experimental Therapeutics programme, Spanish National Cancer Research 
Centre, Madrid, Spain, 2) Instituto de Biomedicina de Sevilla (IBiS), HUVR/CSIC/ 
Universidad de Sevilla,  Sevilla, Spain, 3) Biotechnology programme, Spanish 
National Cancer Research Centre, Madrid, Spain, 4) Consejo Superior de 
Investigaciones Cientificas 
 
*) Corresponding author: Amancio Carnero; Instituto de Biomedicina de Sevilla 
(IBiS), Campus HUVR, Edificio IBIS. Avda. Manuel Siurot s/n.  41013, Sevilla, Spain 
email: acarnero@ibis-sevilla.es; Phone: +3495592111;  
 
 
 
 
 
 2 2 
ABSTRACT 
PIM kinases are a family of serine/threonine kinases composed of three different 
isoforms (PIM1, PIM 2 and PIM 3) that are highly homologous. Their expression is 
mediated by the JAK/STAT signalling pathway, providing survival and cell cycle 
transition signals. PIM kinases are heavily targeted for anticancer drug discovery. 
However, very little is known about the relative contribution of the different 
isoforms to the tumorigenesis process in vivo, and how their individual inhibition 
might affect tumour growth. Taking advantage of genetically modified mice, we 
explored whether the inhibition of specific isoforms is required to prevent 
sarcomas induced by 3-methylcholanthrene carcinogenic treatment. We found 
that absence of Pim2 and Pim3 greatly reduced sarcoma growth, to a similar 
extent to the absence of all 3 isoforms. This model of sarcoma generally 
produces bone invasion by the tumour cells. Lack of Pim2 and Pim3 reduced 
tumour-induced bone invasion by 70%, which is comparable with the reduction 
of tumour-induced bone invasion in the absence of all 3 isoforms. Similar results 
were obtained in MEFs derived from these knockout mice, where double Pim2/3 
knockout MEFs already showed reduced proliferation and were resistant to 
oncogenic transformation by the Ras oncogene. Our data also suggest an 
important role of Gsk3β phosphorylation in the process of tumorigenesis. 
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INTRODUCTION 
 
The PIM kinases are a family of serine/threonine kinases that regulate cell 
proliferation and survival [1, 2] and are highly conserved through evolution in 
multicellular organisms. This family of kinases is composed of three different members 
(Pim1, Pim2 and Pim3) that are highly homologous at the amino acid level, [3] yet 
differ partially in their tissue distribution [4]. Functional redundancy of the three PIM 
kinases has been shown in vitro [5, 6] and in vivo [7].  
 
Unlike other serine/threonine kinases, the PIM family members are tightly regulated 
at the level of transcription and translation [3]. Their expression is mediated by the 
JAK/STAT signalling pathway, which is activated by various cytokines and hormones 
[1, 2, 8-10].  
 
The PIM kinase family members are considered oncogenes and have been 
implicated in tumorigenesis either alone or functioning synergistically with c-Myc [11, 
12]. Initially, elevated levels of PIM1 kinase were discovered in leukemia and 
lymphoma tumours [13-15]. However, more recently, PIM1 was found to be 
increased in solid tumours, including pancreatic and prostate cancer, squamous 
cell carcinoma, gastric carcinoma, colorectal carcinoma, liver carcinoma [16, 17], 
and recently liposarcoma [18]. Increased levels of PIM2 kinase have been detected 
in various lymphomas as well as in prostate cancer. Several  in vitro studies also 
connected PIM2 kinase with liver cancer [3]. PIM3 kinase has been found aberrantly 
expressed in malignant lesions of endoderm-derived organs, liver and pancreas and 
also in Ewing’s sarcoma [3]. Recent studies have correlated PIM1 kinase with 
chemoresistance in prostate cancer cells, which is a common occurrence in more 
aggressive, hormone-refractory prostate cancers [19, 20].  PIM1 kinase has also 
been linked to hypoxia-promoted genetic instability in solid tumours facilitating cell 
survival, resulting in tumours with a more aggressive phenotype [21]. 
 
Although the PIM kinases have been identified as oncogenes in transgenic models, 
by themselves they are only weakly transforming. However, they have been shown 
to greatly enhance the ability of c-myc to induce lymphomas [11, 12, 22, 23]. It is 
understood that mere overexpression of MYC induces an apoptotic response, which 
has to be overcome to permit oncogenesis [11, 14, 15]. PIM kinases (PIM1 and PIM2) 
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have been shown to counteract this MYC-induced apoptosis by phosphorylating 
MYC, thus increasing its protein stability, and consequently its transcriptional activity 
[1]. The overexpression of either PIM1 or PIM2 in factor–dependent haematopoietic 
cells makes them resistant to apoptosis induced by interleukin-3 withdrawal [24-26], 
probably through phosphorylation and inactivation of the proapoptotic protein BAD 
[25, 27]. PIM kinases mediate their physiological activities through phosphorylation of 
a wide range of cellular substrates which, due to the functional redundancy of the 
PIM kinase family, greatly overlap. Previously described phosphorylation targets 
include SOCS-1 [28], runt-related transcription factor 1 (RUNX1) and RUNX3 [29]; cell 
cycle regulators such as p21waf1 and p27kip1 CDK inhibitors [30, 31], cdc 25A 
phosphatase [32] and the kinase cTAK/MARK3/Par1A, and transcriptional repressors 
(HP1), activators (NFATc1 and c-Myb) and coactivators (p100) [33-37]. More 
recently, PIM2 has been shown to phosphorylate the ribosomal protein 4E-BP1, 
causing its dissociation from eIF-4E, which may affect protein synthesis as eIF-4E is a 
rate-limiting factor [28]. Interestingly, several of the mentioned substrates are shared 
with AKT kinases, and PIM and AKT often phosphorylate the same residues [1, 2] .   
 
Interestingly, animals deficient in Pim1 are viable and show only a minor defect in 
haematopoiesis [38, 39], suggesting that PIM1 contributes to haematopoietic cell 
growth and survival, although its role is probably secondary to other signalling 
pathways.  More importantly, mice lacking expression of Pim1, Pim2 and Pim3 are 
viable and fertile, although they show a profound reduction in body size at birth and 
throughout postnatal life [7]. In addition, the in vitro response of distinct 
haematopoietic cell populations to growth factors is severely impaired. These results 
indicate that members of the PIM protein family are important but dispensable 
factors for growth factor signalling [7]. 
 
Together, these studies suggest that PIM kinases may play a distinct role in tumour 
formation in vivo, implying that they may be novel targets for cancer therapy [40]. 
 
However, very little is known about the relative contribution of the different isoforms 
to the tumorigenesis in vivo, and how their individual inhibition might affect tumour 
growth. Taking advantage of genetically modified mice, we explored whether the 
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inhibition of specific isoforms is required to prevent tumour growth either in vitro, in 
MEFs or in vivo in tumours induced by 3-methylcholantrene carcinogenic treatment.  
 
MATERIALS AND METHODS 
Culture Conditions and cell line conservation 
All cell lines were grown in DMEM culture medium supplemented with glutamine 
(Sigma/Gibco), 10 % FBS (Sigma/Genycell), 40 U/ml penicillin, 40 U/ml streptomycin 
and 1 µg/ml fungizone (Gibco/Invitrogen), further referred to as complete medium. 
Cells were grown on 10-cm ø plates and split when a confluent monolayer of cells 
was observed. Retroviral infection of cells was performed as previously described 
[41]. Selection of transfected or infected cells was carried out with 2µg/ml 
Puromycin.  
 
Generation of MEFs  
Mouse embryonic fibroblasts (MEFs) were generated from mouse embryos (day 
12.5) of FVB wild-type mice and genetically modified mice for Pim1, 2 and 3. After 
eliminating the head and liver (which were lysed and used for genotyping), the 
embryo was mechanically disaggregated and trypsinised for 10 min at 37ºC. The 
adherent cells were grown in DMEM (Sigma) supplemented with 10% fetal bovine 
serum (FBS) from Sigma and 1% penicillin G sulphate/ streptomycin on 10-cm ø 
culture plates. Cells were immortalised using the 3T3-protocol. Once immortalised, 
one clone of each genotype was selected for further analysis.  
 
3T3-protocol. Was performed as previously described [42]. Briefly, every 3 days cells 
were trypsinized, counted and replated at 1 million live cells per 10cm plate. 
 
Proliferation, growth under low serum conditions, foci formation, saturation density 
and clonability assays were performed as previously described in [43, 44]. 
 
Maintenance of mouse colonies 
All animals were kept in the CNIO animal facility according to the norms for animal 
welfare. 
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Genotyping of mouse lines 
Pim1, 2 and 3 KO mice were genotyped by PCR using the standard PCR protocol for 
transgenic mice and PCR protocols provided by M. Narwijn (NKI-Netherlands) for the 
triple KO-Pim mice [7]. Subsequently, Pim mutants ( KO) were identified by PCR: the 
Pim1 alleles were detected using Pim1 and Neo primers (Pim1For, 
5`AAGCACGTGGAGAAGGACCG-3_; Pim1Rev, 5´GACTGTGTCCTT GAGCAGCG-3_; 
NeoA, 5`CGTCCTGCAGTTCATTCAGG-3_), the Pim2 alleles with Pim2 and Pgp 
primers (Pim2For, 5`CACCGCGTCACGGATAGACG-3_; Pim2Rev, 
5`CCCACCTTCCACAGCAGCG-3_; HygroFor, 5_AGCACTCGTCC 
GAGGGCAAAGG-3_; Pim2Rev2, 5_-CACGGTGGACCAGCCTAGC-3_), and the 
Pim3 alleles with Pim3 and lacZ primers (Pim3Sp1, 5’ CTGGACC 
AAATTGCTGCCCAC-3_; Pim3Sp4, 5`GGATCTCTGGTTCAAGTATCC3_; LacZ1 
5’CGTCACACTACGTCTG-AACG-3_; LacZ2, 5`CGACCAGATGATCACACTCG-3_). 
 
mRNA expression  
We analysed the expression of the Pim1, Pim2 and Pim3 transcripts in tumours by 
reverse transcription-PCR (RT-PCR). For this, total RNA was isolated from 3-
Methylcholanthrene-induced sarcoma using TriZol (Gibco BRL), treated with DNase, 
and reverse transcribed with random hexamer primers (Promega) and avian 
myeloblastosis virus-reverse transcriptase (Roche). The cDNA was amplified in a 
single PCR using for Pim1 primer combinations (mPim1fwRT 5’ 
ATGCTCCTGTCCAAGATCAACTC-3_; and Pim1revRT 5’ CTCCAGGATCAGG 
ACGAAACTGT-3_;) for Pim2 (Pim2fwRT 5` ATGTTGACCAAGCCTCTGCAGG-3_; and 
Pim2revRT 5´ GCTCAAGGACCAGCATGAAGC-3_;) and for Pim3 (Pim3fwRT 5` 
ATGCTGCTGTCCAAGTTCGGCT-3_; and Pim3revRT 5´ GCT 
CGAACCAGTCCAGCAAGC-3_). As a control, mouse Gapdh was amplified in the 
same PCR using the primers GapdhFw (5` AAGGTCGGTGTGAACGGATT-3_) and 
GapdhRev (5’ TTGCTGGGGTGGGTGGTC-3_).  
 
Carcinogenesis induced by 3-Methylcholanthrene 
The carcinogen 3-Methylcholanthrene (3MC) was dissolved in sesame oil (Sigma) at 
a final concentration of 10 mg/ml. The solution was heated up to 100°C for 1 h and 
mixed vigorously in order to completely dissolve the 3MC. Mice of 3-5 months of age 
were injected with 1 mg (100 µl) of 3MC once into the right hind leg and later 
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examined twice a week. The mice were sacrificed when the tumour reached 1 cm 
in diameter.  
 
Necropsy and pathological analysis 
Once sacrificed, tissues for histological and molecular analysis were taken. Tissues 
meant for molecular analysis were frozen in carbonic ice and later stored at -80ºC. 
Tissues for histological analysis were fixed in 10% formalin for 24h, dehydrated and 
embedded in paraffin.  2-µm cuts were taken off and dyed with haematoxylin and 
eosin or different primary antibodies: KI-67 prediluted (Master Diagnostica -
0003110QD), Caspase 3 1:400 (R & D Systems - AF835), Cyclin D1 1:75 (DAKO - 
M3635), p211:300 (Santa Cruz – sc-397-G) and p53 1:200 (CM5p) (Leica - NCL-p53-
CM5p). As secondary antibodies the following were used: Omnimap anti-rabbit 
prediluted (Ventana – 760-4311), horseradish peroxidase goat anti-rabbit 1:50 (Dako 
– P0448), and biotinylated IgG rabbit anti-goat 1:200 (Dako – E0466).  
 
Statistical data analysis 
The computer program GraphPad Prism was used for all statistical analysis. To 
determine the statistical significance of tumour growth and bone invasion, one-way 
student’s T test analysis was used. To determine the statistical significance of survival 
curves the Mantel-Cox test was used.  
 
Analysis of protein expression 
The cells were washed twice in 1x PBS, pelleted for 30 seconds at 14000x g and lysed 
in lysis buffer (Tris-Hcl pH 7.5 50 mM, NP40 1%, glycerol 10%, NaCl 150mM, complete 
protease inhibitor cocktail, 2 mM; Roche). Total protein from frozen mouse tissue 
(maintained at -80ºC) was extracted after mechanical tissue disintegration using a 
sterile plastic piston in 1ml lysis buffer. After centrifugation, supernantant protein 
extracts were aliquoted and stored at -80°C until use. 
 
The amount of protein was determined by Bradford assay using BSA (bovine serum 
albumin) as a standard. The appropriate protein quantity was dissolved in Laemli 
buffer (Tris-HCL pH 6.8 62.5mM, glycerol 10%, SDS 1%, 2-mercapto ethanol 5%, 
bromphenol blue 0.0025%) and the proteins were separated in SDS-PAGE gels (12%) 
before they were blotted onto Nitrocellulose Transfer membrane (Whatman - 
 8 8 
Protrans). The proteins were visualised via the Odyssey LI-COR system. The primary 
antibodies used were: p53 1:1000 (Cell Signalling - 2524), 4E-BP 1:1000 (Cell Signalling 
- 9644), p4E-BP Thr37/46 1:1000 (Cell Signalling - 9459), Gsk3β 1:1000 (BD Transduction - 
610202), pGsk3βSer9 1:1000 (Cell signalling – 9336L), p27Kip 1:1000 (BD Pharmingen - 
610241), AKT 1:2000 (Cell Signalling – 9272), pAKTSer473 1:1000 (Cell signalling – 4051L), 
Erk1/2 1:1000 (Cell Signalling – 4695S), pErk1/2 Thr202/Tyr204 1:1000 (Cell Signalling – 
9106L), actin 1:5000 (Sigma – A5441), tubulin 1:10000 (Sigma – T6557). The secondary 
antibodies used were goat anti-rabbit Alexa Fluor 680 1:5000 (Invitrogen – A21057) 
and donkey anti-mouse IRDye 800CW 1:5000 (Rockland Inc. – 605-731-002). 
 
RESULTS 
Effect of PIM loss in vitro. 
First, we generated MEFs from double pim2/3 knockout (KO) mice (DKO) or from 
mice lacking all three isoforms (TKO), in parallel with isogenic wild-type MEFs. To that 
end, we first immortalised MEFs from all genotypes. MEFs followed similar senescence 
kinetics and were immortalised with similar frequency irrespective of the genotype 
(not shown). Once immortalised, MEFs were grown in media with optimal (10%) or 
suboptimal (0.5% and 2%) concentrations of serum (Figure 1A). At 0,5%, all MEFs 
showed very slow growth but no apoptosis, irrespective of the Pim isoforms that were 
expressed. At 2% of serum we observed clear differences in the growth of MEFs 
depending on the genotype. TKO MEFs showed poor growth compared with wild-
type MEFs, while DKO MEFs showed intermediate proliferation. The differences 
between DKO and TKO increase in respect to wild-type MEFs at 10% serum 
concentration (Fig 1A).   
 
However, these differences were more dramatic in MEFs infected with virus-carrying 
oncogenic RasV12 (Fig 1B). To that end, MEFs were infected with viruses carrying 
oncogenic RasV12 or empty vectors. MEFs carrying RasV12  were seeded as before in 
optimal or suboptimal growth conditions. At low serum doses, all MEFs, irrespective 
of their genotype, were unable to grow, showing high apoptosis. However, at 10% 
serum, WT MEFs expressing RasV12 grew fast, while TKO and DKO MEFs grew initially 
but stopped growth with high apoptosis after the initial rounds of duplication (Fig 
1B). 
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These data suggest that loss of Pim kinases might rend cells resistant to oncogenic 
transformation. To examine this hypothesis we transfected WT, TKO and DKO MEFs 
with oncogenic RasV12 and measured the number of foci formed. In this assay, 
combined loss of Pim2 and Pim3 is sufficient to block the foci formation induced by 
RasV12 (Fig 1C). TKO MEFs grow forming a non-homogeneous layer of cells, making it 
difficult to assess the foci formation. 
 
To compare the data among the three genotypes and to explore the functional 
relevance of each individual Pim kinase in vitro we decided to perform saturation 
density analysis. Immortal non transformed MEFs have contact inhibition stopping 
growth once the monolayer is formed. However, oncogenically transformed MEFs 
continue growth after the monolayer is formed increasing the density of cells. We 
observed that the growth of DKO and specially TKO MEFs is lower than the growth of 
WT cells (Fig. 1E, lanes C). To compare the individual role of each kinase isoform in 
this assay we expressed ectopically Pim1, Pim2 or Pim3 into wild type MEFs, or MEFs 
lacking Pim2 and 3 (DKO) or lacking all three Pim isoforms (TKO). We observed that 
the increased expression of one isoform of Pim kinases into Pim containing MEFs (WT 
or DKO) does not alter significantly the saturation density of control cells (Fig. 1E, 
hatched bars). However, in TKO MEFs, the recovery of Pim activity is sufficient to alter 
growth  forming monolayer (data not shown) and increase the saturation density to 
levels similar to DKO cells (Fig. 1E, hatched barrs).  Furthermore, we measured the 
response of these cells to oncogenic transformation with Hrasv12. Oncogenic 
transformation with Ras, as expected, increases saturation density in WT MEFs, and 
the increase in one of the Pim isoforms does not seem to provide any advantage 
(Fig 1E, solid bars). In DKO cells expressing only Pim1, Ras does not increases 
saturation density, correlating with the results observed in Fig. 1C. However, 
expressing Ras in MEFs that recovered the expression of 2 isoforms increase the 
saturation density to levels similar to WT cells (Fig. 1E, solid bars). Finally, in TKO MEFs, 
the expression of Ras does no increase the saturation density in any of the cultures 
expressing only one isoform (Fig.1E, solid bars). Our data indicate that at least the 
expression of 2 isoforms is necessary to provide ability to support oncogenic 
transformation. Only overexpression of Pim1, in the absence of Pim2 and 3 seems to 
provide some benefit in the presence of oncogenic Ras. 
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Effect of PIM loss in vivo after carcinogenic treatment. 
 
To evaluate whether Pim kinases play a relevant role in the process of 
sarcomagenesis induced by the carcinogen 3-Methylcholanthrene (3MC), we 
performed intramuscular injection of 3MC, which produced sarcoma tumours with 
an onset of tumour growth at approximately 98 days after inoculation.  An in deep 
evaluation of the time to tumour first observation showed that wild type tumours 
appear in average around 12-20 days earlier than DKO or TKO tumours respectively. 
Since this first sight, tumours took an average of 9 days in wild-type mice to reach 
the end point of 1.7cm3 ( ca. 10% of mouse weight ), indicating a rapid growth of 
these tumours (Fig 2A). However, in DKO it took an average of 21 days to reach the 
same size, while in TKO mice the tumours reached this size in 32 days after onset of 
tumour growth (Fig 2A). This significant time increase indicated that lack of Pim2 and 
Pim3 kinases is sufficient to produce a significant delay in the growth of the 
sarcoma. Additional loss of Pim1 only produces an additional marginal delay. This 
slow sarcoma growth rate was reflected in the survival of the mice. DKO and TKO 
mice treated with 3MC died significantly later than wild-type mice (Fig.2B). This was 
due to the slower growth rate of the tumour, since the sarcomas appeared at the 
same time in all three genotypes (data not shown).  
 
To confirm the relative contribution of each isoform to sarcomagenesis we analysed 
whether the tumour generated by the carcinogenic treatment in each mouse 
derived from true KO cells, or whether they maintained the relative expression of the 
Pim isoforms. We collected mRNA from all the tumours and evaluated the presence 
of individual Pim isoforms' RNA expression (Fig 2C). We observed that the sarcoma 
originated in wild-type mice maintained expression of all 3 pim isoforms, while DKO 
expressed only pim1. Tumours originated in TKO mice did not express any pim 
isoform. 
 
The analysis of the sarcomas from all 3 genotypes showed that 3MC activated p53 
in DKO and TKO MEFs to a similar extent to in WT MEFs (Fig 3A), which was expected 
from the DNA-damage activity of 3MC. As a consequence, all tumours carried 
mutated p53 (Fig 3B). All tumours, independently of the genotype, showed similar 
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levels of KI67, as it corresponds to fast-growing tumours but with very heterogeneous 
distribution (Fig 3C). This large variability among tumours precluded any conclusion 
from this marker. However, the percentage of cyclin D1 positive cells, another 
proliferation marker, showed that the number of proliferating cells in wild-type 
tumours was higher than in DKO and TKO mice (Fig 3C and data not shown). 
Although this increase was not statistically significant due to the variability among 
tumours, it showed a clear trend that tumours of DKO and TKO mice were less 
proliferative. The reduced levels of cyclin D1 might explain the reduced proliferation 
rate of the tumours.  Similarly, all tumours contain caspase 3 staining (Fig 3C). 
However, as in the case of KI67, the large variability among tumours precluded any 
conclusion regarding increased apoptosis. 
 
To study the mechanism implicated in the reduction of growth rate in pim-deficient 
tumours, we analysed the relative levels of proteins that are direct or indirect targets 
of Pim kinases and might be involved in slowing the cell cycle. Pim kinases 
phosphorylate p27kip1, inducing its degradation [31], and might alter the protein 
translation through 4EBP-1 [45, 46]. On the other hand, Pim3-induced tumours show 
increased levels of cyclin D1 [47] and active Gsk3β alters cyclin D1 stability by 
enhancing its degradation [48]. Furthermore, since AKT has been reported to be 
situated downstream of Pim in some models [49], we also measured the 
phosphorylation status of these proteins (Fig 4).  
 
We did only see minimal differences in 4E-BP1 phosphorylation among the tumours 
of the different genotypes, with reductions in the DKO and TKO tumors (Fig 4A and 
4B). We observed also slightly lower levels of pErk and p27kip1 in most DKO and all 
TKO tumours we analysed (Fig 4A and 4B). However, the analysis of 
Gsk3β phosphorylation at ser9 (inactive form) by Western blot showed that this 
residue is not phosphorylated in most DKO and all TKO tumours (Fig 4 A and 4B). Only 
one out of five DKO tumours showed phosphorylated Gsk3β at ser9, while none of 
the analysed TKO tumours showed ser9 Gsk3β  phosphorylation.  By contrast, AKT 
phosphorylation did not show significant variations among tumours (Fig 4a and 4B), 
indicating that the effect on Gsk3β is not due to inactive Akt in Pim-null tumours. 
Levels of other proteins such as MAP kinases did not show variations in the tumours 
from different genotypes either (Fig 4A).  To explore whether that effect on ser9 
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Gsk3β phosphorylation was a general effect due to Pim absence we analyzed 
Gsk3β in MEFs from all three genotypes (Fig 4C). All MEFs showed similar content on 
Gsk3β and Gsk3β phosphorylated at Ser9, indicating that loss of Gsk3β 
phosphorylation at Ser9 occurs during the tumorigenic process. 
 
Loss of Pim kinases reduces bone invasion by sarcoma 
One interesting property in our 3MC-induced sarcomas was the microscopically 
observed bone invasion (Figure 5A). Sarcoma cells are able to degrade bone and 
invade bone marrow. In over 80% of tumours induced in wild-type animals we 
detected bone invasion by these sarcomas (Figure 5B). However, the microscopic 
analysis showed that lack of Pim2 and 3 reduced the percentage of sarcomas 
invading bone to 31%. Lack of all three isoforms reduced bone invasion to 17% 
(Figure 5A), confirming the relevance of these kinases in the process. Furthermore, 
we have detected that these tumors have reduced expression of MMP9 
metaloproteinase correlating with the decreased bone invasion we observed 
(Figure 5C). 
                    
 
DISCUSSION 
 
PIM kinases are an active target for drug discovery research, with most compounds 
focused on the PIM1 isoform due to its known implications in tumorigenesis. 
However, especially in vivo, little is known regarding the specific contribution of 
each isoform to tumorigenesis. Taking advantage of genetically modified mice, we 
explored whether the inhibition of specific isoforms is required to prevent sarcomas 
induced by 3-methylcholanthrene carcinogenic treatment. We found that absence 
of Pim2 and Pim3 greatly reduced sarcoma growth, to a similar extent to the 
absence of all 3 isoforms. Similar results were obtained in MEFs derived from these 
knockout mice, where double Pim2/3 knockout MEFs already showed reduced 
proliferation and were resistant to oncogenic transformation. To block bone invasion 
by the tumour, although the absence of all 3 isoforms is necessary to achieve the 
maximum effect, depletion of Pim2 and Pim3 seems to be sufficient to achieve a 
large reduction of the invasive effect.  
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We observed that sarcomas arising from Pim-defective mice grow significantly 
slower, correlating with reduced proliferation markers, suggesting reduced 
proliferative capacity. It has been shown that PIM1 phosphorylates Cdc25A, thereby 
increasing its phosphatase activity and the activity of cyclin D1-associated kinases, 
which results in cell cycle progression [32]. The Cdc25C-associated kinase 1 (C-TAK1) 
is a potent inhibitor of Cdc25C, a protein that actively promotes cell cycle 
progression at the G2/M phase. By phosphorylating C-TAK1, PIM1 inhibits its activity 
and eventually advances the cell cycle [50]. Furthermore, PIM1 can phosphorylate 
p21waf1, another molecule involved in cell cycle progression, at its threonine residues, 
resulting in its relocation to the cytoplasm and enhancing its protein stability [30, 51]. 
These effects are associated with increased cell proliferation. Thus, it is tempting to 
speculate that PIM can promote cell cycle progression and thus eventually 
contributes to carcinogenesis by modulating the function of molecules that regulate 
cell cycle progression. 
 
Our data showed a reduction of cyclin D1 in Pim-null tumours correlating with a 
decrease in the proliferative capabilities of these tumours. Furthermore, we also 
observed a partial inhibition of 4E-BP1 phosphorylation and slightly lower levels of 
pErk in the DKO and TKO tumours (Fig 4A and 4B). It is possible that the addition of 
those mild effects contributed to reduced proliferation, slowing the tumour growth 
rate. 
 
However, the most important mechanistic feature observed in our model is the loss 
of Gsk3β phosphorylation at Ser9 (inactive form) in most tumours of Pim-depleted 
mice, but not in MEFs of the same genotype. Absence of Gsk3β Ser9 
phosphorylation will maintain high Gsk3β activity, reducing cell cycle transition and 
glucose metabolism [48, 52]. This residue has been shown to be phosphorylated by 
Akt [48]. It is possible that Akt activation lies downstream of Pim, as has been 
described previously [49]. Therefore, loss of Pim might abolish Akt activation and 
subsequent Gsk3β phosphorylation. However, analysis of tumours showed similar 
levels of Akt activation in Pim-null tumours, suggesting that Gsk3β Ser9 residue 
phosporylation depends on a kinase different from Akt. It is possible that Pim itself 
phosphorylates Gsk3β at Ser9 and inactivates the protein, since Akt and Pim share 
many protein substrates [1-3]. On the other hand, Gsk3β is also a substrate of PP2A 
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[53-55], which has been recently described as a target of Pim kinases [56]. Therefore, 
loss of Pim kinases might increase the levels of PP2A, leading to Gsk3β 
dephosphorylation. Furthermore, loss of Pim expression might increase levels of PP2A 
activity, which may mediate the levels of c-Myc and the phosphorylation of proteins 
needed for increased protein synthesis. Both of these changes could have a 
significant impact on tumour growth [56]. Whichever it is the mechanism, it occurs 
only as a consequence of the tumorigenic process in the absence of Pim, since Pim 
null MEFS maintain Gsk3β phosphorylation at Ser9 residue, suggesting that there is no 
redundancy in this Gsk3b phosphorylation, and therefore, this protein can be a 
good therapeutic target for invasion in Pim dependent tumors. 
 
One of the most interesting pieces of data found in our work is the correlation of Pim 
kinases with the process of bone invasion in vivo. Absence of Pim kinases blocks the 
process of bone invasion induced by the 3MC-induced sarcoma, and the genes 
seem to act in an additive manner, since absence of Pim2 and Pim3 produces only 
a partial effect and the absence of all three is necessary to achieve the maximum 
effect. In agreement with our data, siRNA interference of PIM1 and PIM2 reduced 
PC3 migration in vitro by around 50% while inhibition of all 3 PIM kinases by DHPCC-9 
(a specific pan PIM inhibitor) reduced  migration of PC3 in vitro by 90% [57]. In 
addition, overexpression of any PIM family member has the opposite effects by 
enhancing cell motility [57]. Silencing of PIM3 was also reported to reduce 
endothelial cell spreading, migration and vascular tube formation, further 
supporting that this kinase can stimulate metastatic and/or angiogenic potential of 
cancerous cells [58]. In addition, PIM1, but not PIM2, was shown to regulate homing 
and migration of bone marrow cells, possibly via phosphorylation-mediated 
modification of CXCR4 expression in the cell surface [59]. The substrates and 
signalling pathways regulated by PIM kinases, that contribute to enhancing the 
motility of adherent cancer cells remain, however, to be elucidated. Recently, the 
NFAT transcription factors, identified as PIM targets [35] have been implicated in 
tumour cell migration and invasion [60]. Since NFAT is also a target of Gsk3β, it is 
tempting to speculate that lack of ser9-Gsk3β phosphorylation in Pim-null tumours 
contributes to reduced migration by maintaining low levels of NFAT activation.  
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Besides our work, several other features justify the use of PIM as a cancer target; its 
overexpression in various types of tumours, its role in the regulation of pathways 
considered relevant in cancer, as well as the fact that blocking PIM1 function by 
introduction of dominant negative PIM1 sensitises pancreatic cancer cells to 
apoptosis induced by glucose deprivation under hypoxia [21]. Moreover, dominant 
negative PIM1 reduces tumorigenicity in pancreatic cancer cells and HeLa 
xenograft mouse models.  These and other data have led to the synthesis of PIM 
inhibitors that have recently entered clinical trials. 
 
Inhibitors of PIM are of interest as potential therapeutic agents [5, 19, 45, 61, 62]; 
therefore, the understanding of the process that can be targeted by PIM inhibition is 
of great importance to define the potential activity of these compounds. However, 
there is some degree of redundancy among PIM kinases that should be studied 
while defining the specificity of the pharmacological compounds. The levels of 
expression of the different PIM family members vary among tumour types. PIM1 and 
PIM2 are mostly overexpressed in leukemia and lymphomas. PIM1 is also 
overexpressed in some solid tumours such as prostate, pancreas and colon. PIM3 
overexpression has been observed in melanoma, pancreatic and gastric tumours. 
The possibility of overlapping substrates and the potential compensatory nature of 
the different PIM family members as demonstrated by the triple knockout mouse 
model suggests that the inhibition of all isoforms may be more effective than 
targeting individual isoforms. In our genetic model, higher activity is achieved in the 
absence of all family members although sarcoma growth is already significantly 
reduced in PIM2- and 3-depleted mice. 
 
Since both the PI3K and PIM signalling pathways converge on the regulation of 
many signalling proteins that are common for AKT and PIM, it is possible that some 
redundancy among these pathways also occurs in tumours. In fact, It has been 
described that PIM inhibitors synergise with mTOR of PI3K inhibitors [45, 46]. Dual 
treatment with the compounds resulted in decreased phosphorylation of 4E-BP1 
and BAD proteins as well as an increase in apoptosis. These data suggest that a 
combination of drugs that selectively target PI3K/AKT and PIM may have potential in 
treating tumours.  
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FIGURE LEGENDS 
 
FIGURE 1: A) Proliferation of immortalised MEFs under different serum 
conditions. 5x103 cells of each genotype were grown under different 
serum conditions (10%, 2% and 0.5%, respectively). Every 48hrs for 10 days 
a time point was taken. Cells were fixed and the number of cells 
counted as a relative measure of absorbance (see M&M). B) Proliferation 
of immortalised MEFs infected with RasV12 under different serum 
conditions. Cells of each genotype were infected with viruses carrying H-
RasV12.After antibiotic selection (puromycin) 5x103 cells were seeded and 
grown under different serum conditions (10%, 2% and 0.5%, respectively). 
Cells were fixed and the number of cells counted as a relative measure 
of absorbance (see M&M). C) Foci formation. Cells of the different 
genotypes were transfected with the plasmid pBabepuro-HRasV12 
carrying the RasV12 oncogene and grown for 2 weeks, changing the 
medium every 2 days. Cells were then stained with methylene blue to 
visualise the foci (see M&M). D) Activation of MAPK (pMAPK) by 
oncogenic RasV12  expression in WT or DKO MEFs. Cells of each genotype 
were infected with viruses carrying H-RasV12. After antibiotic selection 
(puromycin) 5x105 cells were lysed according to M&M and total protein 
extracted. Then, western blot to identify MAPK phosphorylation 
performed. E) Relative role of Pim isoforms in MEFs saturation density. 
Cells of each genotype (WT, DKO, TKO) were transfected with the 
different Pim isoform as indicated, under the same constitutive promoter. 
After selection the different mass cultures were tranfected with a plasmid 
carrying H-RasV12. After selection, the different mass cultures were 
seeded and grown under 10% serum conditions until they reach 
confluence. Then, the cells were cultured in the same plate for one more 
week changing media every 2 days. After this time, cells were fixed, 
stained and the number of cells counted as a relative measure of 
absorbance (see M&M). 
 
FIGURE 2: Sarcomagenesis in Pim-KO mice after 3-Methylcholanthrene 
injection. Mice were injected with 3-Methylcholanthrene (3MC) as 
described in M&M. Animals were monitored twice per week after onset 
of tumour growth in the first animal was observed. When tumours 
reached the final size (1,7cm3) animals were sacrificed for a humane 
endpoint. A) Days of tumour growth from the first sign of growth onset to 
the final tumour size of 1,7cm3. B) Percentage of survival of the treated 
mice from the injection of 3MC until the humane endpoint. C)  Relative 
expression of the PIM isoform mRNA in tumours of mice treated with 3MC. 
RNA was extracted from tumours and a reverse transcriptase PCR was 
performed to obtain cDNA, which was amplified using specifically 
designed primers. PCR fragment length was checked on 1, 5% agarose 
gels. 
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FIGURE 3: Characterisation of 3MC-induced sarcoma. A) Activation of 
p53 by 3-Methylcholanthrene (3MC). Pre-immortalised MEFs were treated 
with 10 µM 3MC. Total protein was extracted at each time point 
indicated in hrs and p53 expression was determined by Western blot. B) 
Immunohistochemistry of tumours for p53. All tumours were hybridised 
with antibodies against p53. Mutant p53 is recognised by strong nuclear 
staining indicating stabilisation of the p53 protein. C) 
Immunohistochemistry of KI67, Caspase 3 and Cyclin D1 in 3MC-induced 
sarcoma. Several different fields for each tumour were hybridised with 
antibodies against the proliferation markers KI67 and Cyclin D1 and 
apoptotic marker caspase 3. Proliferation markers KI67 and Cyclin D1 
show similar high staining in every genotype with a high intra- and 
intertumoral variability. Apoptosis marker Caspase 3 shows low activation 
regardless of the tumour’s genotype but also a high variability within 
each tumour and among different tumours.  
 
FIGURE 4: Western blot analysis of Pim kinase targets. A) Western blot 
analysis of Pim kinase targets in tumors. For Western blot analysis of direct 
or indirect Pim kinase targets, whole cell protein was extracted from 
freshly resected tumors from mice and levels of different proteins were 
determined by Western blot. Western blot of the phosphorylated proteins 
recognises phophorylation at the following residues:  p4E-BP at Thr37/46, 
pGsk3β at Ser9, pAkt at Ser473, pErk1/2 at Thr202/Tyr204. 2 tumors per genotype 
are shown. B) Quantification of the levels of the different proteins analyzed. 
Each graph shows the relative levels of the protein indicated p4E-BP 
(phosphorylated protein at Thr37/46 related to total p4E-BP), pGsk3β 
phosphorylated Gsk3β at Ser9 related to total pGsk3β), pAkt( phosphorylated 
Akt at Ser473 related to total Akt), pErk1/2 (phosphorylated Erk1/2 at 
Thr202/Tyr204 related to total Erk1/2), p27 (total p27 related to tubulin). Graphs 
show average and St. Dev. of levels in all tumours analyzed as indicated in text. 
C) Western blots analysis of pGsk3β at Ser9 in MEFs. Whole cell protein was 
extracted from MEFs and levels of proteins were determined by Western 
blot. One representative MEF clone per each genotype is shown.  
 
FIGURE 5: Depletion of Pim kinases reduces bone invasion by 3MC-
induced sarcoma: A) haematoxilyn & eosin staining of sarcoma with bone 
invasion. Tumour shown was extracted from wild-type mice. B) 
Percentage of mice that showed bone invasion of sarcoma. Significantly 
more wild-type mice show bone invasion of sarcoma compared with 
mice depleted of Pim kinases. C) Western blots analysis of MMP9 in tumors. 
Whole cell protein was extracted from MEFs and levels of different proteins 
were determined by Western blot. One representative MEF clone per 
each genotype is shown. D) Quantification of the levels of MMP9 in tumors. The 
graph shows the relative levels of the MMP9 protein related to tubulin. Graphs 
show average and St. Dev. of levels in all tumours analyzed as indicated in text. 
 23 
 
Figure 1 
 24 
 
Figure 2 
 
 
 
 
 
Figure 3 
 
 25 
 
Figure 4 
 
 
Figure 5 
